Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.

Blood · 2024 · PMC10862366 · PMID 37616575

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In each comparison, CD200R-CD28 switch CAR T cells showed a nonsignificant trend to further enhancement compared with CD200RDN.

also in 5,406 other papers

a positive trendno p-value reported

The CD200RDN approach showed mixed results in vitro and a positive trend in vivo.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.